There are currently no approved medications for frontotemporal dementia (FTD) and existing treatments for Alzheimer’s (AD) have limited efficacy and focus primarily on relieving symptoms rather than slowing the underlying disease. Thus, there is a major demand for new treatments, but, despite significant efforts, few drug candidates have shown promising results.

Cogentis’ unique solution is to target a key brain enzyme called CDK5 that is hyperactivated in brains with FTD, AD as well as other tauopathies and  plays a key role in disease progression. Our lead compound, CT-526, inhibits abnormal CDK5 activity and is one of the only candidates that targets all the major hallmarks of the selected neurodegenerative diseases: beta amyloid plaques and neurofibrillary tangles leading to cell death. In a pre-clinical AD animal model, CT-526 reversed memory loss as well as other brain deficits and significantly extended lifespan, with no detectable toxic side effects.